Page last updated: 2024-12-06

irganox 1010

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Irganox 1010, also known as pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate), is a hindered phenolic antioxidant widely used in polymers and other materials to prevent degradation caused by oxidation. It is synthesized through a multi-step process involving the reaction of pentaerythritol with 3,5-di-tert-butyl-4-hydroxyhydrocinnamic acid. Irganox 1010 effectively scavenges free radicals, thereby inhibiting chain reactions that lead to polymer degradation. Its high effectiveness and compatibility with various polymers have made it a crucial component in numerous applications, including plastics, rubber, and fuels. Research on Irganox 1010 focuses on understanding its mechanism of action, optimizing its performance, and exploring potential environmental and health effects. The compound's impact on the environment and potential toxicity are areas of ongoing study.'
```

pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate): has antioxidant activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64819
CHEMBL ID3187856
SCHEMBL ID30209
MeSH IDM0132908

Synonyms (100)

Synonym
AC-15274
AKOS005444166
irganox 1010
hydrocinnamic acid, 3,5-di-tert-butyl-4-hydroxy-, tetraester with pentaerythritol
naugard 10
ra 1010
irganox 1010ff
irganox 1010fp
phenosane 23
einecs 229-722-6
fenozan 22
tetrakis(3-(4-hydroxy-3,5-di-tert-butylphenyl)propionyloxymethyl)methane
ralox 630
sumilizer bp 101
pentaerythritol, tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)
dovernox 10
neopentanetetrayl 3,5-di-tert-butyl-4-hydroxyhydrocinnamate
phenosan-23
tetrakis(methylene(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)methane
irganox 1040
benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, 2,2-bis((3-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1-oxopropoxy)methyl)-1,3-propanediyl ester
anox 20
hydrocinnamic acid, 3,5-di-tert-butyl-4-hydroxy-, neopentanetetrayl ester
anox 20am
tetrakis(((beta-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl)oxy)methyl)methane
mark ao 60
tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamoyloxymethyl)methane
ao 60
adk stab ao 60
brn 2035465
ir 1010
tetraalkofen bpe
bp 101
fenozan 23
pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate)
STK367172
pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate), 98%
AO3 ,
benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, 2,2-bis[[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1-oxopropoxy]methyl]-1,3-propanediyl ester
3-{[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl]oxy}-2,2-bis({[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl]oxy}methyl)propyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate
6683-19-8
[3-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxy]-2,2-bis[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxymethyl]propyl] 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate
FT-0659922
tetrakis[methylene-3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate]methane
P0932
pentaerythritol tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate]
dtxsid1027633 ,
tox21_301970
NCGC00255211-01
cas-6683-19-8
dtxcid007633
ec 229-722-6
pentaerithritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)
255pif62ms ,
benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, 1,1'-(2,2-bis((3-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1-oxopropoxy)methyl)-1,3-propanediyl) ester
unii-255pif62ms
2,2-bis(((3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl)oxy)methyl)propane-1,3-diyl bis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate)
pentaerythrityl tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)
pentaerythritol 4-hydroxy-3,5-di-tert-butylphenylpropionate
pentaerythritol 3-(4-hydroxy-3,5-di-tert-butylphenyl)propionate (1:4)
pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate
plastic additive 2
pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate [inci]
pentaerythrityl tetrakis(3,5-di-tert- butyl-4-hydroxyhydrocinnamate)
pentaerythrityl tetrakis (3,5-di-tert-butyl-4-hydroxyhydrocinnamate)
antioxidant 1010 ,
irganox-1010
pentaerythritol tetrakis ester with 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionic acid
plastic additive 2 [usp-rs]
tinogard ttdd
tinogard tt
pentaerthrityl tetra-di-t-butyl hydroxyhydrocinnamate
pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)
pentaerithritol tetrakis[3,5-di-tert-butyl-4-hydroxyhydrocinnamate]
SCHEMBL30209
W-104737
3-([3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyl]oxy)-2,2-bis(([3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyl]oxy)methyl)propyl 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate #
benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, 1,1'-[2,2-bis[[3-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1-oxopropoxy]methyl]-1,3-propanediyl] ester
tetrakis [methylene (3,5-di-t-butyl-4-hydroxyhydrocinnamate)] methane
pentaerythritol tetrakis[3-(3',5'-di-tert-butyl-4'-hydroxyphenyl)propionate]
pentaerythrityl tetrakis-3-(3',5'-di-t-butyl-4'-hydroxyphenyl)propionate
lowinox pp35
tetrakis[methylene(3,5-di-tert-butyl-4-hydroxyhydrocinnamate)methane]
CHEMBL3187856
mfcd00059345
plastic additive 2, united states pharmacopeia (usp) reference standard
plastic additive 09, european pharmacopoeia (ep) reference standard
2,2-bis((3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyloxy)methyl)propane-1,3-diyl bis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate)
2,2-bis[[[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl]oxy]methyl]propane-1,3-diyl bis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate]
SY052363
irganox1010
AS-13857
AMY37985
Q27253913
CS-W011369
2,2-bis(((3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl)oxy)methyl)propane-1,3-diylbis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate)
tetrakis-(methylene-(3,5-di-(tert)-butyl-4-hydrocinnamate)) methane
plastic additive 2 (usp-rs)
PD132638
tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyloxymethyl]methane

Research Excerpts

Overview

Irganox 1010 is a common commercial antioxidant (polymer additive) used in the manufacturing of polyolefin materials for container closure systems.

ExcerptReferenceRelevance
"Irganox 1010 is a common commercial antioxidant (polymer additive) used in the manufacturing of polyolefin materials for container closure systems."( Identification of leachable impurities in an ophthalmic drug product originating from a polymer additive Irganox 1010 using mass spectroscopy.
Blinder, A; Gollapalli, R; Patel, M; Singh, G, 2018
)
1.42

Dosage Studied

ExcerptRelevanceReference
" A cell culture irritation test was dosed with a positive control, negative control and PTTC."( Localized delivery of a lipophilic proteasome inhibitor into human skin for treatment of psoriasis.
Arbiser, J; Banga, AK; Coulon, R; Gujjar, M, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care3

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Dead Sea Naturals Facial Moisturizer Broad Spectrum SPF 20 -- 1.7 fl ozDead Sea NaturalsBeauty & Personal Carebutylene glycol, aminomethyl propanol, citric acid, ascorbyl palmitate, ascorbyl glucoside, ascorbic acid, cetearyl alcohol, citric acid, tocopherol, ethylhexylglycerin, tocopherol, vitamin E, glyceryl stearate, glycerin, dimethicone, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, lactic acid, niacinamide, phenoxyethanol, propylene glycol, salicylic acid, beta-sitosterol, sodium benzoate, sodium citrate, sodium hydroxide, squalene, stearyl alcohol2024-11-29 10:47:42
Dead Sea Naturals Skincare Starter Kit -- 1 KitDead Sea NaturalsBeauty & Personal Carecaprylyl glycol, butylene glycol, aminomethyl propanol, methylpropanediol, citric acid, ascorbyl palmitate, alanine, allantoin, ascorbyl glucoside, ascorbic acid, bisabolol, cetearyl alcohol, cetyl alcohol, cetyl palmitate, chlorphenesin, citric acid, cocamidopropyl betaine, tocopherol, panthenol, pro vitamin B5, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycine, dimethicone, hexyl cinnamal, hydroxyethylcellulose, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, isopropyl myristate, kaolin, lactic acid, linalool, niacinamide, phenoxyethanol, peg-40 stearate, propylene glycol, salicylic acid, beta-sitosterol, sodium benzoate, sodium citrate, sodium hydroxide, sodium lactate, squalene, stearyl alcohol, trehalose, urea, zinc oxide2024-11-29 10:47:42
Mineral Fusion Concealer Refillable Palette - Indulgence -- 0.21 ozMineral FusionBeauty & Personal Caretocopherol, tocopherol, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, glyceryl caprylate, CI 778912024-11-29 10:47:42

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency25.95320.000657.913322,387.1992AID1259377; AID1259394
estrogen nuclear receptor alphaHomo sapiens (human)Potency8.56690.000229.305416,493.5996AID743075; AID743077; AID743079
aryl hydrocarbon receptorHomo sapiens (human)Potency27.49100.000723.06741,258.9301AID743122
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency29.375219.739145.978464.9432AID1159509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (16.67)18.7374
1990's0 (0.00)18.2507
2000's5 (20.83)29.6817
2010's12 (50.00)24.3611
2020's3 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.31 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index84.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]